Emily Kaiser Maharjan, Assistant Managing Editor

Paul Chous, MA, OD, FAAO, gives key takeaways from his 2023 SECO presentation on diabetes: then and now.

Chris Wroten, OD, shares highlights from the hands-on laser workshop he co-led during SECO 2023.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

Shalu Pal, BSc, OD, FAAO, shares key takeaways from the contact lens zpanel discussion she participated in.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key highlights from his portion of the "Presbyopia management panel," during SECO 2023 in Atlanta.

BRIM Biotechnology’s BRM421 is a first-in-class regenerative peptide and could relieve signs and symptoms of dry eye disease in as little as 2 weeks.

First 1-Day Lens that combines DigitalBoost and Aquaform technologies designed to deliver comfort for ‘always on’ digital lifestyles

Andrew Morgenstern, OD, FAAO, FNAP, sits down to discuss the inaugural IKA Keratoconus Symposium in Scottsdale, Arizona, in April 2023.

A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

The next-generation compound of atropine does not contain preservatives or boric acid and can be stored at room temperature for up to 180 days.

The Biosciences group of the Centre for Ocular Research and Education (CORE) determined protein deposits on rigid gas permeable contact lens via radioactive counts by using a radiolabeled lysozyme in an artificial tear solution.

Patrick Mooney, CEO of SpyGlass Pharma, sits down to discuss the 6-month first-in-human clinical trial data of their drug delivery platform with bimatoprost, which is implanted during routine cataract surgery.

Phentolamine ophthalmic solution 0.75%, or Nyxol, receives a PDUFA date of September 28, 2023, for the indication of reversal of pharmacologically induced mydrasis.

Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.

Flavio Mantelli, MD, PhD, Chief Medical Officer at Dompé, shares about the company's role in nerve growth factor (NGF) applications in ophthalmic disease and other human indications.

SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.

CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

All new and existing IDOC inventory management accounts will receive an additional annual benefit as part of their initiative to increase optical profitability in independent practices.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

Two leaders in optometry are coming together to expand their suite of services for independent practices.

Two novel, dropless technologies for keratoconus and dry eye disease make major advances with more to come later in 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

The patented AR lens coating creates thinner, stronger lenses than the alternative, and is now available to patients who love Transitions lenses.

The lens giant pairs precision vision of freeform-optimized lenses with the cost benefit of standard single vision lenses.

In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.

Marc R. Bloomenstein, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Ruth Shoge, OD, MPH, FAAO, shares key takeaways from her EyeCon 2022 presentation, "Diversity in practice, creating an inclusive and equitable workspace."

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.